US2010204087A1PendingUtilityA1
Tribonectins
Est. expiryApr 23, 2019(expired)· nominal 20-yr term from priority
Inventors:Gregory D. Jay
A61P 41/00A61P 9/00A61P 43/00A61P 17/02A61K 38/00A61K 38/1709A61K 48/00A61P 19/10A61P 19/02C07K 14/47C07K 14/475
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
Claims
exact text as granted — not AI-modified1 - 45 . (canceled)
46 . A method of reducing the coefficient of friction between bearing surfaces comprising administering to a bearing surface a composition comprising a tribonectin polypeptide comprising the sequence set forth in SEQ ID NO: 3, or a peptide mimetic thereof, which comprises a covalent, non-peptide bond.
47 . The method of claim 46 wherein said tribonectin polypeptide further comprises one or more repeats of the amino acid sequence of SEQ ID NO: 4.
48 . The method of claim 46 wherein said composition is characterized as reducing the coefficient of friction between bearing surfaces in vitro.
49 . The method of claim 46 wherein said tribonectin or peptide mimetic thereof is characterized as reducing the coefficient of friction between bearing surfaces in vivo.
50 . The method of claim 46 wherein the sequence comprises the amino acid sequence of
SEQ ID NO: 3 and O-linked oligosaccharide side chains.
51 . The method of claim 50 wherein said side chains are N-acetylgalactosamine-galactose.
52 . The method of claim 46 wherein said tribonectin polypeptide comprises an amino acid sequence having at least one but less than 76 subunits, wherein
(a) each subunit comprises at least 7 amino acids; (b) the amino acid sequence of said subunit comprises at least one threonine and has at least 50% identity to SEQ ID NO: 3, wherein a non-identical amino acid is a conservative amino acid substitution; (c) plural subunits comprise β(1-3) Gal-GalNAc moieties; and (d) at least 10% by weight of said polypeptide comprises O-linked oligosaccharides.
53 . The method of claim 46 wherein the molecular weight of said polypeptide is in the range of 220 to 280 kDa.
54 . The method of claim 46 wherein said polypeptide is expressed from a fragment of a megakaryocyte stimulating factor gene.
55 . The method of claim 46 wherein said polypeptide comprises amino acids 200-1140, inclusive, set forth in SEQ ID NO: 1.
56 . The method of claim 46 wherein said polypeptide comprises amino acids 200-1167, inclusive, set forth in SEQ ID NO: 1.
57 . The method of claim 46 wherein said polypeptide comprises amino acids 200-1212, inclusive, set forth in SEQ ID NO: 1.
58 . The method of claim 46 wherein said polypeptide comprises amino acids 200-1263, inclusive, set forth in SEQ ID NO: 1.
59 . The method of claim 46 wherein said polypeptide lacks amino acids 1-24, inclusive, set forth in SEQ ID NO: 1.
60 . The method of claim 46 wherein said polypeptide lacks amino acids 67-104, inclusive, set forth in SEQ ID NO: 1.
61 . The method of claim 46 wherein said composition further comprises hyaluronic acid.
62 . The method of claim 46 wherein said bearing surfaces comprise tissue surfaces.
63 . The method of claim 46 comprising administering said composition to a human in a form suitable for the inhibition of tissue adhesion formation.
64 . The method of claim 46 comprising administering said composition to a human in an amount sufficient to lubricate bearing human tissue surfaces.
65 . The method of claim 64 comprising placing said composition between first and second human tissue surfaces having reduced lubrication.
66 . The method of claim 46 comprising administering said composition in an amount sufficient to lubricate a human tissue surface in contact with an artificial device.
67 . The method of claim 66 wherein said artificial device is an implant.Join the waitlist — get patent alerts
Track US2010204087A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.